- Home
- ZEPP vs XGN Comparison
ZEPP vs XGN Comparison
Compare ZEPP & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- XGN
- Stock Information
- Founded
- ZEPP 2013
- XGN 2002
- Country
- ZEPP China
- XGN United States
- Employees
- ZEPP N/A
- XGN N/A
- Industry
- ZEPP Computer Manufacturing
- XGN Medical Specialities
- Sector
- ZEPP Technology
- XGN Health Care
- Exchange
- ZEPP Nasdaq
- XGN Nasdaq
- Market Cap
- ZEPP 57.5M
- XGN 49.4M
- IPO Year
- ZEPP N/A
- XGN 2019
- Fundamental
- Price
- ZEPP $3.50
- XGN $2.75
- Analyst Decision
- ZEPP
- XGN Buy
- Analyst Count
- ZEPP 0
- XGN 1
- Target Price
- ZEPP N/A
- XGN $7.00
- AVG Volume (30 Days)
- ZEPP 33.4K
- XGN 26.1K
- Earning Date
- ZEPP 11-18-2024
- XGN 11-11-2024
- Dividend Yield
- ZEPP N/A
- XGN N/A
- EPS Growth
- ZEPP N/A
- XGN N/A
- EPS
- ZEPP N/A
- XGN N/A
- Revenue
- ZEPP $237,238,260.00
- XGN $56,660,000.00
- Revenue This Year
- ZEPP N/A
- XGN $9.98
- Revenue Next Year
- ZEPP $18.83
- XGN $13.63
- P/E Ratio
- ZEPP N/A
- XGN N/A
- Revenue Growth
- ZEPP N/A
- XGN 7.05
- 52 Week Low
- ZEPP $2.06
- XGN $1.30
- 52 Week High
- ZEPP $8.40
- XGN $3.71
- Technical
- Relative Strength Index (RSI)
- ZEPP 50.55
- XGN 42.70
- Support Level
- ZEPP $3.66
- XGN $2.90
- Resistance Level
- ZEPP $4.38
- XGN $3.03
- Average True Range (ATR)
- ZEPP 0.28
- XGN 0.18
- MACD
- ZEPP -0.01
- XGN -0.03
- Stochastic Oscillator
- ZEPP 35.29
- XGN 2.27
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in two segments: Xiaomi Wearable Products and Self-branded products & others. The product portfolio includes smartwatches and fitness bands. The majority is from Self-branded products & other segments. It generates majority of the revenue from Xiaomi Wearable Products segment.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.